Deputy Chief and Attending, Thoracic Surgery
Vice Chair for Translational Research, Department of Surgery
Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center
Co-Director, Mesothelioma Program
Memorial Sloan Kettering Cancer Center, NY.
My research focuses on tumor immunology, chimeric antigen receptor (CAR) T-cell therapy, oncolytic viral therapy, and combination immunotherapy for cancers. Over the years, we have developed clinically-relevant orthotopic pleural mesothelioma mouse models and modelled biological therapies in these models. This research has yielded mechanistic data that has been translated and is now in CAR T-cell and combination immunotherapy clinical trials for patients with pleural mesothelioma.
My research has progressed to clinical trials and resulted in >210 publications including in Cancer Cell, Cancer Discov, FASEB, J Clin Invest, J Clin Oncol, J Natl Cancer Inst, Nat Med, and Sci Transl Med. In addition to serving on medical journal editorial boards, I am the Deputy Editor for Molecular Therapy Oncolytics. I serve as a member of national peer-review committees including NCI, DoD, PCORI, National health institutions of Austria, Belgium, Ireland, Italy, Poland, Netherlands, Switzerland, and the United Kingdom. I am an elected member of the Fleischner Society, American Society of Clinical Investigation, and American Surgical Association. I serve on international committees including the American Society of Cell and Gene Therapy, NCI thoracic cancers steering committee, International Association for the Study of Lung Cancer, and the American Association for Thoracic Surgery. In my laboratory, I mentor MDs, MD/PhDs, and PhDs in thoracic oncology research, including visiting scholars from international institutions.
Prof Fraser Brims is a Consultant Respiratory Physician and Head of Department at Sir Charles Gairdner Hospital and Director of Early Years Clinical Skills at Curtin Medical School. He is chair of the WA Mesothelioma Registry and is Deputy Director of the Institute for Respiratory Health where he heads the Occupational and Respiratory Health research group. His has a clinical and research interests in occupational and asbestos related diseases, and early lung cancer detection. He leads the WA Asbestos Review Program, the largest lung cancer early detection program in Australia.
Luana Calabrò presently works as clinical associate at the Medical Oncology and Immunotherapy Unit, Center for Immuno-Oncology, University Hospital of Siena, Italy.
She obtained her MD from the Medical School, University Hospital of Messina, Messina, Italy (1995). In 1996, Dr Calabrò held a Postdoctoral position at the Department of Biomedical Science and Oncology, Hospital of Orbassano, Torino, Italy. In 1999, she obtained her Board Certification in Haematology. During 2000–2001, Dr Calabrò, held a Postdoctoral position at the Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy. She subsequently held the position as researcher in charge of the Flow Cytometry Laboratory, Department of Hematology, Oncology and Molecular Medicine, National Health Institute, Rome, Italy (2001–2004), culminating in her current appointment as Clinical Associate (since 2004). In 2008, Dr Calabrò obtained her Board Certification in Oncology. She has authored more then 70 international scientific publications in books, monographs, and peer-reviewed Journals including Lancet Oncology, Lancet Respiratory Medicine, Cancer Immunology Immunotherapy, J Immunotherapy, J Clin Oncol, Clin Cancer Res, Cell Death Differ, Plos One. Additionally, She is Co-Investigator for numerous solid malignant Phase 1–3 trials with immunotherapeutic agents and new pharmacologic agents, particularly focused on thoracic neoplasms, Dr Calabrò’s research interests include antigenic profiling of human tumour cells and their interaction with the immune system, Her preclinical and clinical research activities are supported by national and international granting bodies.
She was member of the Society of Immunotherapy of Cancer (SITC), and of The American Society of Clinical Oncology (ASCO). She is presently member of the Italian Network for the bio-immunotherapy of cancer (NIBIT), and the International Association for the Study of Lung Cancer (IASLC).
Melvin Chin is a medical oncologist who divides his time between clinical work at Sir Charles Gairdner Hospital and translational research at the National Centre for Asbestos Related Diseases (NCARD) in Western Australia. He has a clinical interest in mesothelioma and a keen research interest in cancer computational biology. Currently, his research focuses on computational approaches for biomarker discovery in mesothelioma using bulk and single-cell genomics.
Dr. Jane Churpek is an Assistant Professor in the Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care at The University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center. Dr. Churpek is a hematologist/oncologist and hereditary cancer expert whose clinical focus is on identifying cancer prone populations and optimizing early detection and cancer prevention for these individuals. She runs a translational research program focused on defining the contribution of rare genetic variation on risk of cancer, how inherited variants interact with environmental exposures to contribute to cancer initiation in those at risk, and how they impact tumor biology and response to treatment.
Liz has enjoyed over 35 years of clinical practice at the University Hospitals of Leicester, 19 of them in thoracic oncology. Currently she is a Consultant Nurse at UHL and is also Head of Services for Mesothelioma UK, the national charity for Mesothelioma.
Liz’s interests within thoracic oncology have always focused on developing the nursing contribution, within the multidisciplinary team, to improve outcomes but also the patient and carer experience across the whole cancer pathway.
Clinically Liz is a core member of the Leicester Thoracic Oncology Multi-disciplinary Team who provide a comprehensive mesothelioma management service to over 200 patients per year.
To meet demand locally and nationally Liz developed an interest in Mesothelioma which resulted in her being the founder of Mesothelioma UK. This national charity was initially hosted by the University Hospitals of Leicester. It has established itself as an essential part of the UK Mesothelioma landscape as a centre of excellence providing specialist information, support and education. The Charity has an annual income of over £1.2m which it uses to fund: - 30 Clinical Nurse Specialist in NHS hospitals around the UK, comprehensive national audit, research grants and provide an extensive range of information, support and education resources.
Liz has held several Honorary university positions, is very active in terms of research, promoting nursing as a career and in pre and post graduate education.
Liz has served 10 years as a committee member (2 years as chair) for the National Lung Cancer Forum for Nurses, 14 years on the British Thoracic Oncology Group steering committee, is a current member of the International Association for the Study of Lung Cancer and is proud to be a founding member of the International Thoracic Oncology Nursing Forum.
Liz has individually, and joint authored a number of publications about lung cancer and mesothelioma and gives up to 25 lectures a year at regional, national and international meetings.
Liz’s contribution has been recognised through several awards. Nurse peers awarded Liz Cancer Nurse Leader of the Year in 2007 and the British Thoracic Oncology Group awarded her a 10 Year Achievement Award in 2012. In HRH Queen Elizabeth’s Birthday honours list in June 2019 Liz was invited to become a Member of the British Empire (MBE) in recognition of her services to patients and cancer research.
Chair of Thoracic Medical Oncology,
Director, Leicester Mesothelioma Research Programme
Cancer Research UK Centre Experimental Medicine Centre
University of Leicester and
University Hospitals of Leicester NHS Trust, UK
Dean Fennell is a Professor & Consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Programme based at the University of Leicester/University Hospitals of Leicester NHS Trust. He is an internationally recognised key opinion leader in thoracic oncology and is currently leading the UK portfolio of studies in relapsed mesothelioma including the pivotal phase III immunotherapy study CONFIRM, and world's first stratified umbrella study for mesothelioma, MiST. He is a planning committee member of the International Association for the Study of Lung Cancer (IASLC), mesothelioma taskforce member for the IASLC, member of the Cancer Research UK population research committee, and steering committee for the British Lung Foundation mesothelioma research network. He has been past-president of the International mesothelioma interest group, past-chair of the NCRI mesothelioma subgroup, and co-author of both the European and UK mesothelioma treatment guidelines. Prof. Fennell is currently the Leicester lead for the groundbreaking Cancer Research UK TraceRx/Darwin/PEACE phylogenetic studies. Prof. Fennell held two prestigious CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at UCL where he was awarded several prizes. He completed medical training in the London Golden circuit (Hammersmith, Brompton, Guy's, St Thomas's), and completed his specialist training at Barts Hospital. Prof. Fennell has published over 100 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature Reviews Cancer, and Proceedings of the National Academy of Sciences.
Dr. Seiki Hasegawa is a Professor, Departments of Thoracic Surgery and Thoracic Oncology, Hyogo College of Medicine, Japan. He performs all kind of general thoracic surgery, including extended resection of lung cancer, minimal invasive thoracic surgery, and particularly, mesothelioma surgery. He graduated from Kyoto University in 1983 and spent 6 residency years at the Shizuoka City Hospital and the National Himeji Hospital. He spent 4 years in his post-graduate course during 1989-1983, including two years at the Department of Cardiothoracic Surgery, Washington University, St. Louis as a transplant research fellow during 1991-1993.
Then he worked 3 years as an assistant professor of the Department of Intensive Care Medicine, Kyoto University. In 1998, he moved to the Department of Thoracic Surgery, Kyoto University and successfully started Lung Transplant Program.
Dr. Hasegawa moved to the Department of Thoracic Surgery, Hyogo College of Medicine in 2004. He started the Hyogo College of Medicine Mesothelioma Surgery Program and has performed more than 200 curative-intent surgery for mesothelioma. Since 2017 he has been the Chief, Department Surgery, and also the Professor, Department of Thoracic Oncology, Hyogo College of Medicine.
He is currently the President of the Japan Asbestos Mesothelioma Interest Group, an Advisory Board of IASLC Staging Committee, and a Board Member of the Japanese Association for Chest Surgery and the Japanese Association for Thoracic and Cardiovascular Surgery.
Dr. Cathy Henshall MN, RGN, MA, PhD is a National Institute for Health Research 70@70 Senior Nurse Research Leader and is responsible for improving the capacity and capability of nurses to undertake research across the UK. She is also a Senior Nursing Research Fellow at Oxford Brookes University and the Head of Research Delivery at Oxford Health NHS Trust. Cathy holds an honorary contract with the Department of Psychiatry, University of Oxford. She is a Principal Investigator on numerous studies and her research interests include cancer survivorship, self-management, mental health and workforce development, with a particular interest in lung cancer and mesothelioma care. Cathy was awarded grant funding from Mesothelioma UK in 2018 and 2019 to carry out research exploring ways to improve mesothelioma follow up pathways, from the perspectives of patients and clinicians. Cathy is on the editorial board of BMC Health Services Research and the Journal of Clinical Nursing. Her clinical background is in oncology nursing.
Dr. Astero Klampatsa graduated with a PhD in Research Oncology (focused in mesothelioma apoptotic and hypoxia pathways) from University of London, UK, in 2011. She then worked as a Research Associate in the CAR Mechanics lab, Department of Oncology at King’s College London, where she got trained in the development and preclinical use of CAR T cell therapies for mesothelioma. Her research was supported by grants from the June Hancock Mesothelioma Research Fund. In 2013, she was awarded a BRC STEM Early Career Award, which allowed her to train as a visiting fellow in vitro 3D mesothelioma models at the Lung Biology Center, UCSF, USA. From 2015-2019 she worked as a Senior Postdoctoral Research Fellow in Professor Steve Albelda’s lab at Perelman School of Medicine, University of Pennsylvania (Penn), USA. Her research focused on developing CAR T cell therapies for mesothelioma and lung cancer, as well as the immunobiology of these malignancies with a focus on the function of tumour-infiltrating lymphocytes (TILs). She joined the Institute of Cancer Research in London, UK as a Team Leader in October 2019. Her Thoracic Oncology Immunotherapy Group focuses on developing new CAR T cell therapies for mesothelioma and lung cancer, as well as investigating phenotypic and functional aspects of the immunobiology of mesothelioma for identification of markers of response to immunotherapy. She has been a visiting senior lecturer at King’s College London since 2015. She is a member of the International Mesothelioma Interest Group (IMIG), the European Association of Cancer Research (EACR) and the International Association for the Study of Lung Cancer (IASLC).
Professor Kang, Seong-Kyu is Chair of Department of Occupational and Environmental Medicine at the Gachon University Gil Medical Center (GUGMC) in Incheon, Korea. Dr. Kang worked for the Korea Occupational Safety and Health Agency (KOSHA) from 1992 to 2016 and served as Vice President and Director General of Occupational Safety and Health Research Institute (OSHRI).
He is Vice President of the International Commission on Occupational Health (ICOH) and the fellow of the Collegium Ramazzini. He launched the journal of Safety and Health at Work (SH@W) indexed in SCIE/SSCI/SCOPUS and serves as the Editor-in-Chief. He is Non-executive Vice President of the Korea Industrial Health Association (KIHA). He was the key responsible person of 31st ICOH Congress held in Seoul in 2015.
Dr. Kang graduated from the Chung Nam National University and completed his residency from the Yonsei University Severance Hospital. He was an Epidemic Intelligence Service (EIS) officer at the US NIOSH. He holds specialties of Occupational and Environmental Medicine and Family Medicine.
Professor Loic Lang-Lazdunski graduated from Xavier Bichat Medical School, University of Paris in 1991. He trained in General Surgery and Cardiothoracic Surgery in the Paris rotation. He was awarded an MD in 1996 and a PhD in Experimental Surgery in 2000. He started his career as Assistant Professor of Cardiothoracic Surgery at the University of Paris in November 1998. He was recruited at Guy’s and St Thomas’ Hospital NHS Trust in London in 2003, where he created and led one of the largest mesothelioma programs in Europe. He was awarded a Chair in Mesothelioma at King’s College London in 2012. He has been involved in several important surgical trials in mesothelioma: MARS, MesoVATS, EORTC-L1205, and has helped colleagues develop mesothelioma programs throughout the world. He pioneered the technique of total pleurectomy/decortication and hyperthermic pleural lavage with povidone-iodine in malignant pleural mesothelioma and has recently reported his 15-year experience with this approach showing no surgical mortality and impressive 5-year survival in more than 150 consecutive patients. He has a keen interest in basic science and molecular oncology in mesothelioma. At present, he collaborates with colleagues and researchers in the National Centre for Mesothelioma Research, Imperial College London to study tumour heterogeneity, mesenchymal transition, genomics and help identify new targets in mesothelioma.
Professor Lee is a clinician scientist whose research program uniquely combines laboratory and clinical research with an active tertiary clinical pleural service which he directs. His track record includes 290+ publications, total citations of >8900, and H-index of 50. He has been an invited speaker in 100+ conferences in 30 countries. His work has changed clinical practice in many aspects of pleural diseases especially in malignant effusions, pleural infection and pneumothorax. He plays a significant role in establishing pleural medicine as a new respiratory subspecialty and has trained many next generation pleural specialists worldwide.
Charles B. Simone, II, MD, FACRO is a Research Professor and the Chief Medical Officer of the New York Proton Center and a Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in using proton therapy to treat mesothelioma and other thoracic malignancies and for reirradiation, and in developing clinical trials and innovative research in thoracic radiation oncology and stereotactic body radiation therapy.
Prior to coming to NYPC, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at University of Pennsylvania and residency in radiation oncology at the National Cancer Institute, NIH, where he served as chief resident.
Dr. Simone is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who has published >320 scientific articles and chapters, given >200 scientific lectures to national and international audiences, and is the national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials (4 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time Association of Residents in Radiation Oncology Educator of the Year Award winner. Dr. Simone Chairs the Proton Collaborative Group (PCG) Executive Committee; PCG Lung Committee; ASTRO Lung Resource Panel Committee; ACRO Recruitment Subcommittee; and NCI/Radiosurgery Society GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group. He is the Editor-in-Chief of Annals of Palliative Medicine.
Keep up to date with Conference News & Alerts.
Receive the latest information about the International Mesothelioma Interest Group Meeting 2020 by entering your information below.
Now you will receive all the latest conference updates straight in your mailbox.Click here to close this window